The effects of varenicline, bupropion, nicotine patch, and placebo on smoking cessation among smokers with major depression: A randomized clinical trial

Paul M. Cinciripini,George Kypriotakis,Charles Green,David Lawrence,Robert M. Anthenelli,Jennifer Minnix,Janice A. Blalock,Diane Beneventi,Chad Morris,Maher Karam‐Hage
DOI: https://doi.org/10.1002/da.23259
IF: 8.128
2022-05-11
Depression and Anxiety
Abstract:Importance Improving treatment outcomes for smokers with major depressive disorder (MDD) can have significant public health implications. Objective To evaluate the safety and efficacy of smoking cessation pharmacotherapy among smokers with MDD. Design Secondary analysis of a randomized, double‐blind, active‐ (nicotine patch) and placebo‐controlled trial of 12 weeks of either varenicline or bupropion with a 12–week follow‐up. Participants Community volunteers 18−75 years of age; smoke 10+ cigarettes/day; with clinically stable MDD (N = 2635) or no psychiatric disorder (N = 4028), from 140 sites in 16 countries. Intervention Twelve weeks of pharmacotherapy (placebo [PLA], nicotine replacement therapy [NRT], bupropion [BUP], varenicline [VAR]) plus brief cessation counseling. Measure(s) Primary safety outcome: the occurrence of ≥1 treatment‐emergent, moderate to severe neuropsychiatric adverse event (NPSAE). Primary efficacy outcome: biochemically confirmed continuous abstinence (CA) during the final 4 weeks of treatment (Weeks 9–12). Results A total of 6653 participants (56% female; 39% MDD) ~47 years old. Risk of NPSAEs did not differ by medication for MDD. MDD had higher risk (p
psychiatry,psychology, clinical
What problem does this paper attempt to address?